Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific (NYSE: BSX) has launched the CHAMPION-AF clinical trial to assess the safety and effectiveness of the WATCHMAN FLX™ device for patients with non-valvular atrial fibrillation (NVAF). This study will involve 3,000 patients at about 150 sites globally, comparing the device against non-vitamin K antagonist oral anticoagulants (NOACs). The trial aims to provide evidence for making the WATCHMAN FLX a potential first-line therapy for stroke prevention. The device offers a one-time solution, crucial for patients who cannot tolerate long-term anticoagulation.
Boston Scientific Corporation (BSX) reported third-quarter 2020 sales of $2.659 billion, a decline of (1.8)% year-over-year. The company faced a GAAP net loss of $(169) million or $(0.12) per share, compared to a profit of $126 million or $0.09 per share last year. Adjusted EPS was $0.37, down from $0.39. Sales decreased across all segments, notably a (16.3)% drop in Interventional Cardiology. New product launches include FDA-approved devices such as the AVVIGO Guidance System and SYNERGY Stent Systems. The company refrained from issuing guidance due to COVID-19 uncertainty.
Boston Scientific (NYSE: BSX) will host a virtual investor update at the 2020 Transcatheter Cardiovascular Therapeutics on October 15, from 1:00 to 2:00 p.m. EDT. Key executives will discuss the cardiovascular portfolio and address investor questions. Additionally, on October 28, the company will conduct a conference call at 8:00 a.m. EDT to review third-quarter financial results for the period ending September 30, with a news release preceding it. Both events will be accessible via the company's investor relations webpage.
Boston Scientific has launched the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems in Europe, designed to provide personalized pain relief for chronic pain sufferers. This new portfolio includes four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs). The WaveWriter Alpha systems support combination therapy, allowing for simultaneous use of different stimulation modalities. With 88% of patients reporting significant pain relief, this launch aims to enhance quality of life for the approximately 100 million people in Europe affected by chronic pain.
Boston Scientific (NYSE: BSX) has launched the ACURATE neo2™ Aortic Valve System in Europe, enhancing transcatheter aortic valve implantation (TAVI) technology. This system offers expanded indications for patients with aortic stenosis, includes new annular sealing technology to minimize paravalvular regurgitation, and simplifies access to complex vessels. Clinical data suggests improved outcomes, with 97.5% of patients experiencing mild or no paravalvular leakage at one year. The system is investigational in the U.S., assessed in the ACURATE IDE trial.
Boston Scientific (BSX) announced an investment agreement for an exclusive option to acquire Farapulse, a company developing a pulsed field ablation system for atrial fibrillation (AF). This innovative system uses electric fields instead of thermal energy to ablate cardiac tissue, offering a more precise treatment method. The FDA granted Breakthrough Designation to Farapulse in May 2019, accelerating its path to market. Boston Scientific's investment aligns with its strategy to enhance its electrophysiology product portfolio, catering to the needs of AF patients.
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and initiated a limited market release of its Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe as of September 9, 2020. This system, designed for treating Parkinson's disease, essential tremor, and dystonia, features MRI compatibility and Bluetooth capabilities. With advanced directional stimulation and new clinician software, the Vercise Genus aims to optimize therapy for over 10 million people affected by Parkinson's globally. Notably, the system is not available for use in the United States.
Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for its Eluvia Drug-Eluting Vascular Stent System, effective October 1, 2020. This designation allows eligible hospitals to receive additional reimbursement for up to three years, enhancing access for patients with peripheral artery disease (PAD). The Eluvia stent system demonstrates superior clinical outcomes, showing lower rates of repeat procedures compared to competitors. This payment support is crucial for improving patient care and boosting hospital incentive.
Boston Scientific (NYSE: BSX) will participate in two virtual investor conferences on September 9 and September 16, 2020. CEO Mike Mahoney will join a Q&A session at the Wells Fargo 2020 Virtual Healthcare Conference, starting at 9:20 a.m. EDT. On September 16, Mahoney, CFO Dan Brennan, and IR VP Susie Lisa will participate in a similar session at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference, beginning at 8:00 a.m. EDT. Live webcasts and replays will be available on the company's investor relations website.
BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for Voraxaze® (glucarpidase). This application aims to authorize Voraxaze® for treating adults and children at risk of methotrexate toxicity due to delayed elimination. The MAA is underpinned by clinical data and real-world experience, having previously treated nearly 3,000 patients in the US since FDA approval in 2012. A decision from the EMA could lead to marketing authorization across the EU and additional countries.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
